Jong Wook Lee

Prof. Jong Wook Lee

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2019 in Blood
Verified
Journal Article
Open access
PDF file
JLJong Wook Lee
Jong Wook Lee
FFFlore Sicre de Fontbrune
Flore Sicre de Fontbrune
LLLily Wong Lee Lee
Lily Wong Lee Lee
VPViviani Pessoa
Viviani Pessoa
SGSandra Gualandro
Sandra Gualandro
AHAnita Hill
Anita Hill
Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor–naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Patients with lactate dehydrogenase (LDH) ≥1.5 times the upper limit of normal and at least 1 PNH symptom were randomized 1:1 to receive ravulizumab or eculizumab for 183 days (N = 246). Coprimary efficacy end points were proportion of patients remaining transfusion-free and LDH normalization. Secondary end points were percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)–Fatigue score, proportion of patients with breakthrough hemolysis, stabilized hemoglobin, and change in serum free C5. Ravulizumab was noninferior to eculizumab for both coprimary and all key secondary end points (Pinf < .0001): transfusion avoidance (73.6% vs 66.1%; difference of 6.8% [95% confidence interval (CI), −4.66, 18.14]), LDH normalization (53.6% vs 49.4%; odds ratio, 1.19 [0.80, 1.77]), percent reduction in LDH (−76.8% vs −76.0%; difference [95% CI], −0.83% [−5.21, 3.56]), change in FACIT-Fatigue score (7.07 vs 6.40; difference [95% CI], 0.67 [−1.21, 2.55]), breakthrough hemolysis (4.0% vs 10.7%; difference [95% CI], −6.7% [−14.21, 0.18]), and stabilized hemoglobin (68.0% vs 64.5%; difference [95% CI], 2.9 [−8.80, 14.64]). The safety and tolerability of ravulizumab and eculizumab were similar; no meningococcal infections occurred. In conclusion, ravulizumab given every 8 weeks achieved noninferiority compared with eculizumab given every 2 weeks for all efficacy end points, with a similar safety profile. This trial was registered at www.clinicaltrials.gov as #NCT02946463.

12 August 2021 in Haematologica
Verified
Journal Article
Open access
PDF file
DNDietger Niederwieser
Dietger Niederwieser
HBHelen Baldomero
Helen Baldomero
NBNosa Bazuaye
Nosa Bazuaye
CBCaitrin Bupp
Caitrin Bupp
NCNaeem Chaudhri
Naeem Chaudhri
WSWael Saber
Wael Saber
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCT were reported by 1,662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6.2% in autologous HCT and 7.0% in allogeneic HCT and bringing the total to 1,298,897 procedures. Assuming a frequency of 84,000/year, 1.5 million HCT were performed by 2019 since 1957. Slightly more autologous (53.5%) than allogeneic and more related (53.6%) than unrelated HCT were reported. A remarkable increase was noted in haploidentical related HCT for leukemias and lymphoproliferative diseases, but even more in non-malignant diseases. Transplant rates (TR; HCT/10 million population) varied according to region reaching 560.8 in North America, 438.5 in Europe, 76.7 in Latin America, 53.6 in South East Asia/Western Pacific (SEA/WPR) and 27.8 in African/East Mediterranean (AFR/EMR). Interestingly, haploidentical TR amounted to 32% in SEA/WPR and 26% in Latin America, but only 14% in Europe and EMR and 4.9% in North America of all allogeneic HCT. HCT team density (teams/10 million population) was highest in Europe (7.7) followed by North America (6.0), SEA/WPR (1.9), Latin America (1.6) and AFR/EMR (0.4). HCT are increasing steadily worldwide with narrowing gaps between regions and greater increase in allogeneic compared to autologous activity. While related HCT is rising, largely due to increase in haploidentical HCT, unrelated HCT is plateauing and cord blood HCT is in decline.

1 May 2013 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JLJong Wook Lee
Jong Wook Lee
JJJun Ho Jang
Jun Ho Jang
JKJIN SEOK KIM
JIN SEOK KIM
SYSung-Soo Yoon
Sung-Soo Yoon
JLJe-Hwan Lee
Je-Hwan Lee
SSSang Kyun Sohn
Sang Kyun Sohn

27 November 2023 in The Lancet Haematology
Verified
Journal Article
Closed access
JLJong Wook Lee
Jong Wook Lee
MGMorag Griffin
Morag Griffin
JKJin Seok Kim
Jin Seok Kim
LLLily Wong Lee Lee
Lily Wong Lee Lee
CPCaroline Piatek
Caroline Piatek
HYHiroki Yamaguchi
Hiroki Yamaguchi

13 September 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
JYJae-Ho Yoon
Jae-Ho Yoon
SPSung-Soo Park
Sung-Soo Park
YJYoung-Woo Jeon
Young-Woo Jeon
SLSung-Eun Lee
Sung-Eun Lee
BCByung-Sik Cho
Byung-Sik Cho
JLJong Wook Lee
Jong Wook Lee
Hemophagocytic lymphohistiocytosis is an overwhelming systemic inflammatory process that is life-threatening if not treated appropriately. We analyzed prognostic factors of secondary hemophagocytic lymphohistiocytosis excluding malignancy. In this retrospective study, we analyzed 126 adult cases between 2001 and 2017. Treatment was based on dexamethasone with or without etoposide and cyclosporine. Patients who achieved complete response at 4 weeks were defined as early-stable responders, those who failed to achieve complete response but showed continuous improvement until 8 weeks as late responders, those whose conditions waxed and waned until 8 weeks as unstable responders. Patients with hemophagocytic lymphohistiocytosis caused by Epstein-Barr virus experienced worse 5-year overall survival compared to autoimmune disease, other infections, and unknown causes (25.1% vs. 82.4%, 78.7%, 55.5%, p<0.001). We observed that overall response rate at 4 weeks was similar, but decreased at 8 weeks in the Epstein-Barr virus subgroup from 75.5% to 51.0%, and finally decreased to 30.6%. Multivariate analysis revealed that 8-week treatment response was the most relevant factor for overall survival. Excluding 8-week response, Epstein-Barr virus, old age, hyperferritinemia, and thrombocytopenia were associated with poor survival. We established a prognostic model with the parameters: low-risk (score 0-1), intermediate-risk (score 2), and high-risk (score≥3). These groups had 5-year overall survival of 92.1%, 36.8%, and 18.0%, respectively (p<0.001). We found that 8-week treatment response was a good predictive factor for overall survival, and that Epstein-Barr virus, old age, thrombocytopenia, and hyperferritinemia were associated with poor survival outcomes. Physicians should take care to identify high-risk patients for appropriate treatment strategies.

5 March 2024 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
ASAnna Sureda
Anna Sureda
PCPaul A. Carpenter
Paul A. Carpenter
ABAndrea Bacigalupo
Andrea Bacigalupo
VBVijaya Raj Bhatt
Vijaya Raj Bhatt
JFJosu de la Fuente
Josu de la Fuente
MKMohamed A. Kharfan-Dabaja
Mohamed A. Kharfan-Dabaja
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to be curative in benign hematologic disorders such as aplastic anemia, sickle cell disease, and thalassemia, among others. Recently, the American Society for Transplantation and Cellular Therapy (ASTCT) published standardized definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism. To attempt broader international consensus, a panel of adult and pediatric physician transplant experts was assembled from European Society for Blood and Marrow Transplantation (EBMT), ASTCT, the Center for International Blood and Marrow Transplant Research (CIBMTR), and Asia-Pacific Blood and Marrow Transplantation (APBMT). Consensus was defined as ≥70% of voting members strongly agreeing or somewhat agreeing with a definition. With few exceptions, there was a consensus to endorse the prior ASTCT definitions. Importantly, we revised existing EBMT and CIBMTR data collection forms to align with these harmonized definitions that will facilitate research and international collaboration among transplant researchers and across transplant registries.